PMID- 20350633
OWN - NLM
STAT- MEDLINE
DCOM- 20100407
LR  - 20100330
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
VI  - 123
IP  - 4 Suppl
DP  - 2010 Apr
TI  - Safety and tolerability of commonly prescribed oral antibiotics for the treatment 
      of respiratory tract infections.
PG  - S26-38
LID - 10.1016/j.amjmed.2010.02.004 [doi]
AB  - Recent data suggest that adverse events (AEs) associated with the use of 
      antimicrobial drugs are a major safety concern, with antibiotics implicated in a 
      significant proportion (approximately 20%) of all drug-related emergency 
      department visits in the United States. Although most of these visits are 
      attributable to allergic reactions (79%), certain commonly prescribed antibiotics 
      are notable contributors to conditions that range in nature from gastrointestinal 
      to neurologic and/or psychiatric--particularly after ED visits are adjusted per 
      outpatient prescription visits. This article reviews medically significant AEs of 
      agents included in the major antimicrobial classes--AEs that may be 
      underappreciated by general practitioners. Considerable attention is devoted to 
      the fluoroquinolone agents. Also discussed are the assessment procedures of 
      regulatory agencies in Europe and the United States that are in place to evaluate 
      antimicrobial safety more accurately. Offsetting potential risks and benefits 
      associated with currently available antimicrobials in a climate in which new 
      agents are desperately needed to combat continually evolving multiresistant 
      pathogens remains an interesting dilemma in antimicrobial therapy.
CI  - Copyright 2010 Elsevier Inc. All rights reserved.
FAU - Lode, Hartmut
AU  - Lode H
AD  - City Hospital Berlin-Zehlendorf, Free University of Berlin, Berlin, Germany. 
      haloheck@zedat.fu-berlin.de
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Cephalosporins)
RN  - 0 (Fluoroquinolones)
RN  - 0 (Macrolides)
RN  - 0 (beta-Lactams)
SB  - IM
MH  - Administration, Oral
MH  - Anti-Bacterial Agents/*administration & dosage/*adverse effects
MH  - Cephalosporins/administration & dosage/adverse effects
MH  - Drug Administration Schedule
MH  - Drug Prescriptions/statistics & numerical data
MH  - Emergency Service, Hospital
MH  - European Union
MH  - Fluoroquinolones/administration & dosage/adverse effects
MH  - Government Agencies
MH  - Humans
MH  - Macrolides/administration & dosage/adverse effects
MH  - Product Surveillance, Postmarketing
MH  - Respiratory Tract Infections/*drug therapy
MH  - Safety
MH  - United States
MH  - United States Food and Drug Administration
MH  - beta-Lactams/administration & dosage/adverse effects
RF  - 104
EDAT- 2010/04/02 06:00
MHDA- 2010/04/08 06:00
CRDT- 2010/03/31 06:00
PHST- 2010/03/31 06:00 [entrez]
PHST- 2010/04/02 06:00 [pubmed]
PHST- 2010/04/08 06:00 [medline]
AID - S0002-9343(10)00099-9 [pii]
AID - 10.1016/j.amjmed.2010.02.004 [doi]
PST - ppublish
SO  - Am J Med. 2010 Apr;123(4 Suppl):S26-38. doi: 10.1016/j.amjmed.2010.02.004.